Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec starts phase III trial of Adentri

Biogen Idec starts phase III trial of Adentri

22nd August 2008

Biogen Idec has commenced a phase III trial of intravenous Adentri (BG9928), which is an A1 receptor antagonist and aimed at treating acute decompensated heart failure (ADHF) sufferers with renal insufficiency.

The randomised, double-blind, multi-centre, placebo-controlled and parallel-group study is intended to assess the safety and efficacy of intravenous Adentri.

It will be dosed up to five days based on body weight – a measure of fluid accumulation and one considered to be an important cause of symptoms for those with heart failure.

According to Dr William Abraham, professor of internal medicine and the director of the division of cardiovascular medicine at the Ohio State University Medical Centre, Adentri has previously shown potential for optimising fluid management without causing harmful effects to renal function.

“Heart failure patients with renal insufficiency are at risk for poor clinical outcomes and are among the most difficult to treat, as currently available therapies negatively impact renal function,” he added.

The American Heart Association says heart failure is the US’ most common cause for hospitalisation and research has shown that over six in ten patients brought in for treatment also have renal insufficiency.

Meanwhile, last month saw Biogen Idec and Elan celebrate the second anniversary of Tysabri and its use as a treatment for multiple sclerosis.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.